Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Explaining biosimilars to our patients

Paul Cornes • 27 Jun 2017
EHA 2017
Rituximab

Paul Cornes, MD, University Hospital Bristol NHS Foundation Trust, Bristol, UK, talks to us about some of the challenges we’ll face now that two biosimilar rituximab agents have been approved for use in the UK. Physicians are now understanding the approval pathway for these drugs and are gaining more trust in the regulators. But we have a lot to learn if we are to convince patients and take them with us on this journey.

More from Paul Cornes

4:16
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
Paul Cornes • 22 Jun 2017
2:24
Are biosimilars as efficacious as their reference drugs?
Paul Cornes • 22 Jun 2017
3:56
Can the dream of affordable cancer care come true?
Paul Cornes • 21 Mar 2017
2:43
Why do we need biosimilars?
Paul Cornes • 21 Mar 2017
The content of VJHemOnc is intended for healthcare professionals